Johnson and Johnson have a monitoring panel reviewing its trial for COVID-19 late stage vaccine trial. one of their patients in the study became ill with an unexplained illness. after AstraZeneca Plc (AZN.L) Also delay trials of its Coronavirus vaccine. the two companies used a similar technology to produce the vaccine. Currently, the information is being reviewed for a few days and that pauses are a normal process during large blind study clinical trials Involving thousands of patients . Johnson and Johnson does not know if the person that felt ill was given a placebo or the vaccine.
This pause is not a regulatory hold that is imposed by health authorities.J&J says review of illness that led to pause of coronavirus vaccine trial could take days
Analyst Price Target on JNJ
▲ (12.45% Upside)
Based on 8 analysts offering 12-month price targets for Johnson & Johnson in the last 3 months. The average price target is $167.25 with a high forecast of $175.00 and a low forecast of $158.00. The average price target represents a 12.45% increase from the last price of $148.73. Source TipRanks
This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.
Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.